Royalty Pharma Raises 2026 Outlook To $3.5 Billion-Plus In Receipts Despite $150 Million Pelacarsen Charge
Third-quarter royalty collections grew 9%, but net income attributable to shareholders fell to $145 million from $284 million.
Royalty Pharma, which buys royalties on drugs sold by other companies, raised its 2026 forecast for Portfolio Receipts to $3,500 million to $3,550 million, from $3,400 million to $3,500 million, as third-quarter collections grew 9% to $890 million. The company announced the results Wednesday in an 8-K; profit fell after a $150 million non-cash write-down tied to Novartis's pelacarsen.
Tremfya and Voranigo lead the quarter
Royalty Receipts, the sales-based payments at the core of the business, rose 9% to $883 million. Tremfya climbed 61% to $80 million and Voranigo 65% to $55 million, with Evrysdi (up 38% to $71 million) and Imdelltra adding to the gain. Evrysdi also benefited from additional royalties acquired in December 2025.
Promacta receipts fell 75% to $9 million on U.S. generic competition, and Imbruvica dropped 24% to $31 million. The new guidance implies Royalty Receipts growth of 10% to 11% for the year and excludes future transactions.
Cost guidance improved too: operating and professional costs are now expected at 5.5% to 6.0% of Portfolio Receipts, from 5.5% to 6.5%. The company says costs are falling from 8.9% in 2025 because the management fee ended when it completed the internalization of its management on May 16, 2025.
Profit halves on the pelacarsen charge
Net income attributable to Royalty Pharma shareholders was $145 million, against $284 million a year earlier. The quarter carried the $150 million non-cash impairment after Novartis said its Phase 3 pelacarsen trial missed its main goal of reducing cardiovascular events in the overall study population.
Net cash from operating activities slipped 2% to $686 million from $703 million. Adjusted EBITDA rose 8% to $840 million, and Portfolio Cash Flow rose 2% to $673 million.
Debt paid down, shares bought back
Royalty Pharma repaid a $380 million term loan in July, cutting total debt principal to $8.8 billion from $9.2 billion at June 30. It ended September with $514 million in cash and repurchased about 1.5 million shares for $87 million in the quarter.
The company, which holds royalties on more than 35 commercial products, said it has announced transactions worth up to $1.9 billion as of November 3, including potential future milestones, with Capital Deployment of $1.6 billion. Third-quarter deals included $100 million each for royalties on Arcutis's Zoryve and Takeda's Mimrylo. CEO Pablo Legorreta said R&D co-funding with large drugmakers, with $1 billion announced this year, is "an important new opportunity for our business."
Royalty Pharma holds its results call at 8:00 a.m. Eastern on Wednesday; Pharvaris's FDA decision date for deucrictibant is April 23, 2027.